Butinib 140 mg (Ibrutinib) Capsule

Introduction: Butinib 140 mg, crafted by Drug International Ltd. and made accessible through Orio Pharma, represents a significant advancement in the realm of blood cancer treatment. The active ingredient, Ibrutinib, is a powerful kinase inhibitor that has revolutionized the approach to managing certain hematologic malignancies.

Description: Ibrutinib, the cornerstone of Butinib 140 mg, belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors. Its mechanism of action involves selectively inhibiting BTK, a key component in the signaling pathways of B-cell cancers, leading to the disruption of cancer cell growth and survival.

Mechanism of Action: Butinib 140 mg works by blocking the activity of BTK, a crucial enzyme in the B-cell receptor signaling pathway. By doing so, it interrupts the signals that drive the survival and proliferation of cancerous B cells, offering a targeted and effective treatment for certain blood cancers.

Clinical Use:

Butinib 140 mg is primarily employed for the treatment of:

• Chronic Lymphocytic Leukemia (CLL): Ibrutinib is prescribed for individuals with CLL, particularly those who have received at least one prior therapy.
• Mantle Cell Lymphoma (MCL): Butinib is indicated for the treatment of MCL in adult patients who have received at least one prior therapy.

Dosage and Administration: Healthcare professionals determine the dosage of Butinib 140 mg based on the specific type of blood cancer, the patient’s overall health, and individual response to treatment. The medication is typically taken orally, with or without food.

Benefits of Butinib 140 mg:

• Effective BTK Inhibition: Butinib 140 mg provides potent inhibition of BTK, disrupting the signaling pathways that fuel the growth and survival of cancerous B cells.
• Prolonged Progression-Free Survival: Ibrutinib has demonstrated efficacy in prolonging progression-free survival in patients with CLL and MCL, offering extended periods of disease control.
• Improved Quality of Life: The use of Butinib contributes to an improved quality of life for individuals living with CLL and MCL, reducing symptoms and enhancing overall well-being.

Manufacture Section: Manufacturer: Drug International Ltd.

Drug International Ltd., the manufacturer of Butinib 140 mg, is dedicated to producing pharmaceuticals of the highest quality. With a commitment to innovation and stringent adherence to standards, Drug International Ltd. plays a pivotal role in ensuring that patients receive reliable and effective medications.

Supplier Section:Supplier: Orio Pharma

Orio Pharma, as the distributor of Butinib 140 mg, serves a crucial role in the distribution and accessibility of this vital medication. Committed to excellence in supply chain management, Orio Pharma ensures that Butinib reaches healthcare providers and patients seamlessly.

Conclusion: In conclusion, Butinib 140 mg (Ibrutinib) signifies a paradigm shift in the treatment of certain blood cancers, offering a targeted and effective therapeutic option. Manufactured by Drug International Ltd. and supplied by Orio Pharma, this medication is not just a treatment; it represents a transformative leap forward in the fight against hematologic malignancies. The precision of Ibrutinib in inhibiting BTK underscores its role as a potent and well-tolerated therapeutic option. The collaboration between Drug International Ltd. and Orio Pharma ensures that this innovative medication is not only manufactured to the highest standards but also made accessible to those who need it the most. As the field of blood cancer treatment continues to advance, Butinib 140 mg exemplifies the progress being made in providing more effective, personalized, and compassionate care for individuals confronting hematologic challenges.